The presence of synchronous metastases at first diagnosis was associated with a significantly poorer OS in the anti-EGFR subgroup compared to patients with metachronous metastatic disease (HR 3.01, 95% CI 1.29–7.04, p < 0.05). This evidence concerns the gene EGFR and metastatic neoplasm.